TVI-Brain-1
- Generic Name
- TVI-Brain-1
- Drug Type
- Biotech
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Phase 2
Suspended
- Conditions
- Glioblastoma Multiforme of Brain
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- TVAX Biomedical
- Target Recruit Count
- 120
- Registration Number
- NCT05685004
- Locations
- 🇺🇸
Center for Neurosciences, Tucson, Arizona, United States
🇺🇸Cedar-Sanai Medical Center, Los Angeles, California, United States
🇺🇸University of Southern California Keck School of Medicine, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath